Fig. 3
Distribution of recurrent Plasmodium vivax infections by treatment group during follow-up. Bar charts display the observed number of participants with and without recurrent P. vivax infection in four treatment groups: chloroquine (CQ; n = 98), artemether–lumefantrine (AL; n = 84), chloroquine plus primaquine (CQ + PQ; n = 93), and artemether–lumefantrine plus primaquine (AL + PQ; n = 79). Recurrence was defined as parasitologically confirmed P. vivax infection occurring ≥ 14 days after completion of initial therapy. Panels summarize recurrence status assessed at Day 28 and at end of follow-up (6 months). Bars represent observed participant counts within each treatment group; no error bars or confidence intervals are displayed, and the figure is descriptive. Abbreviation: CQ; Chloroquine, CQ + PQ; Chloroquine + Primaquine, AL; Artemether/lumefantrine, AL + PQ; Artemether/lumefantrine + Primaquine.
